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ABSTRACT

CRISPR/Cas9-mediated Gene Editing in HERDA Equine
by
Joseph R. Hawkes, Master of Science
Utah State University, 2019

Co-Major Professors: Drs. Zhongde Wang and Dirk Vanderwall
Department: Animal, Dairy, and Veterinary Sciences
To date, no research group has published gene editing in Equine. Heritable Equine
Regional Dermal Asthenia (HERDA) is an autosomal recessive genetic skin disease
found mainly in elite American Quarter Horse breeding lines. HERDA is caused by a
single nucleotide mutation (c.115 G>A) in exon 1 of the peptidyl-prolyl Isomerase B
(PPIB) gene. HERDA-affected horses are not suitable for performing and are oftentimes
euthanized. Any prospect of “breeding out” HERDA from American Quarter Horses is
unlikely, given the wide spread HERDA-causing mutation among elite American Quarter
Horses.
Since no effective treatment exists for HERDA, it representing an opportunity to
use gene editing to correct this genetic disease. In this thesis project, CRISPR/Cas9 and
adenine base editor 7.10-max (ABEmax) were employed to edit the HERDA-causing
mutation in equine fibroblasts. I designed a single guide RNA (sgRNA) to direct
CRISPR/Cas9 to induce double strand breaks (DSBs) 15 nucleotides (nt) downstream of
the mutation which achieved very efficient insertions or deletions (indels) (~90%).
Assisted by a small 100nt. reverse compliment single-stranded donor oligonucleotide as
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template, CRISPR/Cas9 edited the HERDA-causing mutation in equine fibroblasts with
~10% efficiency. Four single-cell derived colonies, out of 41, were established from
transfected cells and genetically characterized, and showed both monoallelic and biallelic
gene editing frequencies of 7.3% and 2.4% respectively. The colonies were
cryopreserved for future animal cloning experiments to produce HERDA-free animals.
Performance evaluation of the cloned animals may also to answer the question on
whether the HERDA mutation is linked to the extraordinary flexibility of joints and super
performance of elite horses.
Lengthening the highly efficient sgRNA that was used with CRISPR/Cas9 by 2
nucleotides broadened the base editing window, giving ABEmax access to the HERDAcausing mutation at protospacer position 19. Horse fibroblasts were transfected with
ABEmax, where single-cell colony selection and sequencing revealed seamless A to G
conversion in 3 out of 20 single-cell colonies. Another 40% of isolated colonies may
have been edited but carry an unspecific PCR band. Further investigation is needed to
determine these genetic alterations.
(74 pages)
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PUBLIC ABSTRACT

CRISPR/Cas9-mediated Gene Editing in HERDA Equine
Joseph R. Hawkes

HERDA (Heritable Equine Regional Dermal Asthenia) is a genetic skin disease
mainly found in Quarter Horses, but also in Appaloosa and American Paint breeds.
HERDA is similar to Ehlers-Danlos syndrome in humans, with symptoms including
stretchy skin, hyperflexible joints, and, unique to HERDA equine, spontaneous skin
sloughing. Horses affected by HERDA are not suitable for performing and are oftentimes
euthanized. Some carriers for the HERDA-mutation are very competitive in the American
Quarter Horse industry, especially in cutting events where it is believed, yet unproven, to
give them an advantage with increased flexibility. It is also possible that the genomic
locus (or loci) that links to the competitive performance traits is located close to the
HERDA-causing mutation, which could lead to the co-segregation of this performance
trait with the HERDA-causing mutation.
Direct-line breeding strategies in the last 30 years have increased the number of
HERDA-affected equine causing this disease to increase in frequency among the Quarter
Horse breed. Since no treatment exists for HERDA, owners often heavily invest in
HERDA horses before the symptoms arise at around two years of age. These horses are
often euthanized to alleviate pain and stress on the horse and to mitigate the costly
upkeep by the owner.
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HERDA-affected horses carry a homozygous single nucleotide mutation (c.115
G>A) in exon 1 of peptidyl-prolyl Isomerase B (PPIB). Gene editing approaches would
be preferable for correcting this genetic disease, since it can precisely correct the
mutation without altering any other genetic traits in the elite horse breeds that have been
heavily selected for. By employing the CRISPR/Cas9 system, we have sought to correct
the HERDA-causing mutation in the PPIB gene. The CRISPR/Cas9 system is comprised
of a bacterial endonuclease protein called Cas9 and a guide RNA sequence to direct Cas9
to target the genome in a sequence-specific manner by introducing DNA double-strand
breaks (DSBs). The introduction of DNA DSBs promotes the activation and recruitment
of homologous recombination (HR)-mediated DNA repair machineries to repair the
broken DNA; if oligonucleotides with the desired DNA sequence are co-delivered with
the CRISPR/Cas9 system into cells, the HR-mediated DNA repair mechanism can
replace the targeted sequence in the genome with the oligonucleotide’s sequence,
therefore, achieving gene correction or editing. We designed sgRNAs to target genomic
sequences in close vicinity of the HERDA-causing mutation and a single-stranded DNA
oligonucleotide containing the normal (wild type) PPIB genotype. Co-delivery of the
CRISPR/Cas9/sgRNA complex with the donor oligonucleotide has successfully led to the
production of gene edited cells. We established single-cell derived colonies from the
edited cells and achieved 7.3% monoallelic and 2.4% biallelic editing frequencies. The
gene edited fibroblasts were cryopreserved as an initial step for future HERDA-free
equine cloning projects to develop the first gene edited horses.
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We also investigated novel approaches to correct the HERDA-causing mutation
by means of Adenine Base Editors (ABEs). Optimized for mammalian expression,
ABEmax is composed of the Cas9 nickase fused to TadA, a tRNA adenosine deaminase
lab-evolved to catalyze A to G base conversions in DNA. Seamless base editing was
achieved in 15% of single-cell derived colonies, correcting the HERDA-causing
mutation, while unusual genotypes were detected in 40% of isolated colonies.
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CHAPTER I
INTRODUCTION

Hereditary Equine Regional Dermal Asthenia (HERDA) is an autosomal
recessive disease of American Quarter horses, with the highest prevalence in reining and
cutting horses (A. Rashmir-Raven, 2013). HERDA is caused by a single-nucleotide
missense mutation (c.115G>A) in exon 1 of the peptidyl-prolyl Isomerase B (PPIB) gene
which codes for cyclophilin B (CypB) protein (Tryon, White, & Bannasch, 2007). The
HERDA-causing mutation alters CypB’s interaction with other collagen-folding
enzymes, delaying collagen folding, decreasing collagen tensile strength, and propagating
disorganized fiber packing (Bowser et al., 2014; Brounts, Rashmir-Raven, & Black,
2001; Grady, Elder, Ryan, Swiderski, & Rashmir-Raven, 2009; Ishikawa et al., 2012).
Symptoms include fragile skin, prone to ulcerative lesions, spontaneous skin sloughing,
hypermobility, subdermal hematomas, and decreased cornea thickness (Badial et al.,
2015; A. M. Rashmir-Raven & Spier, 2015).
In Rashmir-Raven’s study (2013), HERDA-affected equines reportedly begin
showing pathological lesions by age two, when the horse is saddled to begin riding, while
some do not develop the disease until 4-5 years old, or occasionally, never develop
typical skin lesions, though hyperelastic (i.e., “stretchy) skin is present. She found that
occasionally, mildly affected horses are sound enough to compete, while some, aided by
great care, have lived into their late 20’s. Due to increased DNA testing availability and
HERDA awareness, most horses with HERDA are humanely euthanized by age 3, but
Rashmir-Raven notes that often, HERDA is diagnosed after considerable financial and
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emotional investments have been made. She also reports that the number of horses
affected by HERDA is increasing due to the common practice of line breeding carrier
horses, to the point that today, HERDA is one of the most commonly reported inherited
diseases in the equine industry. HERDA-affected Quarter Horses, Appaloosas, and
American Paints are found throughout the world, reported in at least the United States,
Canada, Mexico, Brazil, England, France and the Netherlands (Badial et al., 2015;
Rendle, Durham, & Smith, 2010; Tryon et al., 2009; White & Bourdeau, 2011). Truly,
HERDA is a world-wide issue without a cure.
Gene-editing technology provides an opportunity to correct the HERDA-causing
mutation, as a solution for alleviating animal suffering without euthanasia and
propagating these elite genetic carrier lines without HERDA. Gene editing of
performance horses, either heterozygous or homozygous for the HERDA-causing
mutation, could offer horse breeders more flexibility in selecting mating pairs as edited
clones would be restored to wild-type, free of the mutation.
Originally derived from microbial adaptive immunity, clustered regularly
interspaced short palindromic repeats (CRISPR) has been harnessed to mediate
targeted and efficient modification of virtually any location within the eukaryotic
genome by a short RNA guide (Cong et al., 2013a). In complex with the guide RNA,
CRISPR-associated endonuclease Cas9 can base pair with the sequence of interest,
thereafter inducing double-strand breaks (DSBs) (Jinek et al., 2012). This DNA
cleavage may result in insertions or deletions (indels) which disrupt the gene in an
uncontrollable manner, or through the Homology Directed Repair Pathway, available
with a sister chromatid or provided DNA template which edits the gene (Hsu, Lander,
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& Zhang, 2014). Precise short gene editing (< 50bp) may be achieved by providing the
cells with a short single-stranded oligodeoxynucleotide (ssODN), designed to have
~50-80bp homology arms of varying symmetry around the DSB and sense in relation
to the PAM-containing strand (Paquet et al., 2016; Richardson, Ray, DeWitt, Curie, &
Corn, 2016; Wang et al., 2016). For large insertions/deletions (>100bp), plasmid donors
are commonly used with 800bp homology arms. Co-delivered with CRISPR/Cas9, the
donor ssODN or plasmid instructs the cell repair machinery which mutations to
integrate or retract from the cellular DNA (Yang et al., 2013).
In order to increase editing efficiency and reduce indels, base editor technology
was developed by David Liu’s group at the Broad Institute of MIT and Harvard (Gaudelli
et al., 2017). They describe the Adenine Base Editor (ABE) as a Cas9 nickase fused to
Escherichia coli TadA, a tRNA adenosine deaminase, which acts on DNA instead of its
usual RNA substrate. In the process of A to G conversion, they describe an intermediate
called inosine, which is converted to guanosine along with the complimentary thyminebase converted to cytosine, after either DNA replication or repair. In order to target a
specific adenine base for editing, ABE uses an NGG protospacer adjacent motif (PAM)
and 20nt guide RNA to edit adenine bases within an editing window of positions 13-17
upstream of the PAM sequence.
ABE7.10 was the first ABE version developed by Gaudelli (2017) which
catalyzed an A (adenine) to G (guanine) conversion in ~50% of human cells with very
low INDEL rates (typically ≤0.1%). Although much more efficient than Cas9 nuclease
and ssODN editing, Koblan (2018), from the same group, reported that ABE7.10 editing
bottlenecks in the process of plasmid expression, which reduces base editing efficiency.
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His group optimized ABE7.10 by modification of nuclear localization signals and codon
usage, and ancestral reconstruction of the deaminase component. The resulting ABEmax
editor corrects mutations with ~5 to 7-fold greater efficiency than ABE7.10 and generates
indels rarely (≤1.6%) although elevated from the virtually undetectable indel levels of
ABE7.10.
Another base editing tool was developed by Feng Zhang’s group at the Broad
Institute of MIT and Harvard to convert A to I (inosine) in RNA instead of DNA
(Abudayyeh et al., 2017; Cox et al., 2017). They fused Cas13b RNA nuclease to ADAR,
a human deaminase that catalyzes A to I conversion in RNA, naming it REPAIR (RNA
Editing for Programmable A to I Replacement). They reported that REPAIR can be used
to selectively edit adenosine to inosine in RNA when used in conjunction with a guide
RNA where inosine is read as guanosine by translational machinery. Additionally,
REPAIR does not require PAMs or operate within a base editing window, but rather
requires modification and delivery of a 50bp guide RNA, where a base flip (C) at the
target A directs base conversion optimally at protospacer position 37 (Matthews et al.,
2016). Zhang’s group (2017), developed several versions of REAPIR where a mutation in
the ADAR deaminase domain confers increased specificity, and Cas13b is truncated for
adeno-associated virus (AAV) expression. With these modifications, Cas13b has
powerful potential as a gene therapy tool.
This thesis project is the first to implement CRISPR/Cas9 to correct the
HERDA-causing mutation in equine fibroblasts, in anticipation of cloning the first
gene-edited horses by using the gene-edited fibroblasts as nuclear donors. In parallel,
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research was also carried out to establish DNA and RNA editing techniques in equine
for developing therapeutics for affected horses.
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REVIEW OF LITERATURE

Hereditary Equine Regional Dermal Asthenia
Hereditary equine regional dermal asthenia (HERDA) is an autosomal recessive
skin disorder that affects primarily American Quarter Horses (A. Rashmir-Raven, 2013).
In a clinical study by Borges and associates (2005) in Brazil, they noted that HERDA is
also known as hyperelastois cutis, as it belongs to a group of inherited congenital
connective tissue dysplasias. They reported clinical sign of the disease from three horses
with HERDA, where they found that tender bilateral lesions of their trunk and lumbar
regions cause the horse pain upon handling. They also demonstrated that these sensitive
regions contain hyperelastic skin due to thinner and smaller collagen fibrils which are
loosely organized. In White’s study (2014), it was reported that horses begin showing
additional HERDA disease signs such as skin lesions, seromas, and hematomas by one
and a half years of age, after saddling which commonly causes lesions along the dorsal
aspect in HERDA-affected equine. Rashmir-Raven (2013) also found that HERDAaffected horses have an increased range of motion in their joints and greater ligament
elasticity than other horses.
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A

B

C

D

Figure 1. Clinical signs of HERDA in Affected Equine. A) Spontaneous skin
sloughing in a 2‐year‐old Quarter Horse filly (Hrd/Hrd), typical of a horse severely
affected with HERDA. B) Disfiguring scars on a 6‐year‐old Quarter Horse stallion with
HERDA (Hrd/Hrd) C) An example of ‘doughy’ skin on a 3‐year‐old Quarter Horse
gelding with HERDA (Hrd/Hrd). This horse was gelded at approximately 18 months of
age without ill effects. D) An example of loose, hyperextensible skin on a 3‐year‐old
Quarter Horse gelding with HERDA (Hrd/Hrd). This horse was also gelded at
approximately 18 months of age without ill effects. (Rashmir-Raven and Spier, 2015).

Rashmir-Raven and Spier (2015) later demonstrated that HERDA-affected horses
exhibit loose, stretchy, hyperextensible skin that is easily pulled away from the body
(Figure 1D). They reported that affected areas of the abnormal skin may range from a
small area of 2-3 cm in diameter to 80% of the horse’s body; some skin becomes so
fragile that it sloughs off, leaving disfiguring scars, common among HERDA equine
(Figure 1B). Also, they noted that oddly, some horses do not develop lesions until 4yrs
old or later while other horses appear to never develop lesions, although they exhibit
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hyperextensible skin and signs of discomfort when saddled. Their research indicates that
males appear to be most severely affected. Although HERDA-affected equine show poor
recovery from some wounds, successful healing may occur after routine or traumatic
repair surgeries (Castori et al., 2012).
Rashmir-Raven (2013) reports that other skin conditions may mimic HERDA
phenotype, especially Alopecia (horse baldness), often worrying the horse owners
whether their horses are affected by HERDA. She and Brown (2015) list other skin
conditions sometimes confused with HERDA, which include “Rain Rot” (bacterial skin
infection), mud fever, sweet itch, hives, sunburn, warts, ringworm, mange, or lice.

Figure 2. Joint Hypermobility in HERDA-affected (Hrd/Hrd) Equine. A yearling
American Paint Colt undergoing two types of leg stretches, revealing an abnormal range
of motion (Rashmir-Raven, 2013).

Histopathological Signs and Identification
In separate clinical studies, groups led by Badial (2015), Bowser (2014),
Brinkman (2017), (Gardner, Arnoczky, & Lavagnino, 2011) and Grady (2009) reported
that HERDA-affected equine may show signs of the disease not only in skin and joints
but also the cornea, great vessels, tendinoligamentous structures, and heart valves. They
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also noted that these horses have higher amounts of total soluble collagen than unaffected
horses, osteoarthritic lesions, increased joint inflammation, greater incidence of corneal
opacities, decreased corneal thickness, abnormal collagen fibril arrangement, and weaker
(lower tensile strength) tendinoligamentous tissues and great vessels.

A

B

Figure 3. Dermal Lesions Observable in HERDA-affected Equine. A) Hematoma on
the withers of an affected horse, caused by blood and serum accumulation in the upperdeep dermis. B) Dorsal skin ulcerations complicated by UV radiation and saddle riding
(Tyron et al., 2007).
A group led by Brounts (2001) analyzed tissues from HERDA-affected equine,
and found that thinning and fragmentation of the skin may result in separated skin layers
where the space between layers fills with fluid, forming large blisters (bulla) and
hematomas (Figure 3A). In some areas, the upper half of the skin is completely separated
from the lower half of the deep dermis by a cleft-like space, known as zonal dermal
separations (Figure 4C). Also present in the deep dermis are interstitial
microhemorrhages and increased vascularity (Brounts et al., 2001).
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A

B

C

Figure 4. HERDA Collagen Fiber Organization. Dermal skin biopsy from a 1yr. old
filly affected with HERDA, fixed on a slide an imaged by electron microscopy (TEM;
x54,000). A) Variations in collagen fiber diameter, a trait unique to HERDA, B) collagen
fibers packed in a loose and unorganized fashion, C) cross-section revealing the
separation of the superficial and deep dermis (Brounts et al., 2001).

Potential Environmental Influences on HERDA Equine
The reason for variation in affected horses’ clinical signs is partially unknown,
while potential environmental influences my play a role in severity of the disease. UV
light appears to increase severity of HERDA, by the disease’s manifestation on the dorsal
midline where UV light hits more directly and heat is also more intense (Rashmir-Raven,
2013). UV light exposure disrupts the dermal extracellular matrix by activating matrix
metalloproteinases (MMPs) including collagenases (Rittié & Fisher, 2002). Due to
delayed collagen folding and loosely packed/disorganized collagen fibers, the MMPs
may degrade collagen more rapidly than in humans (A. M. Rashmir-Raven & Spier,
2015). Rashmir-Raven (2013) reports that horses with dermal lesions often show signs of
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recovery after being moved indoors for 2-4 weeks. She also notes that colder weather,
UV light protective sheets, and northern climates also decrease the effects of HERDA (A.
Rashmir-Raven, 2013).
Palliative Treatments
No effective treatment for HERDA exists (White, 2014). Rashmir-Raven and
Spier (2015) suggest that palliative therapy, which focuses on preventing or relieving
symptoms, for HERDA-affected equine, includes administering phenylbutazone and
chondroprotective nutraceuticals. They mention that some horse owners strongly
recommend supplementing HERDA horses with lysine, but its benefits are not medically
confirmed. Rashmir-Raven (2013) suggests that supplementing horses with dietary
copper and vitamin C may help manage HERDA, but concludes that minimizing trauma,
careful wound management, and restriction from heat and sunlight are some of the best
ways to care for HERDA-affected equine.
HERDA Mutation Origin
Hedgepeth (1990) explains that the Quarter Horse breed originated from crosses
between English and Spanish horses as early as 1611 that were originally bred for their
use in short quarter-mile races in colonial America. These horses were later interbred
with the Mustang, where he adds that during the American Westward migration, these
“Quarter Horses”, as they became known, were invaluable for their versatility, strength,
and agility, as they were employed in ranches and cattle management.
Although HERDA was first reported in young Quarter horses in 1978, this
mutation has been traced back to a Quarter Horse foundation sire, Poco Bueno who was
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foaled in 1944 (A. Rashmir-Raven, 2013; Tilstra & Byers, 2002). Rashmir-Raven (2013)
recounts that Poco Bueno was immensely popular, gentle, smart, and easy-to-handle. She
and the American Quarter Horse Association (AQHA) (2010) report that he remained an
influential sire during the 1940s, ‘50s and ‘60s—siring 405 registered foals, 50% of
which were carriers for HERDA. The AQHA (2010) also records that 36 of his offspring
were AQHA champions, 3 of which, as confirmed carriers, were inducted into the
National Cutting Horse Association Hall of Fame, and later, in 1990, Poco Bueno was
inducted posthumously.
A group led by Tryon (2007) concluded that robust breeding of HERDA carrier
stallions has caused inbreeding loops, where many affected horses’ pedigrees trace back
to the popular sires bred in the late 1990s, resulting in higher incidence HERDA-affected
equine. Out of 5000 horses’ DNAs tested, 55 were found homozygous for the HERDAcausing mutation (Hrd/Hrd), whose lineages trace back to Poco Bueno. In a separate
evaluation of 75 HERDA-affected horses, 100% exhibited consanguinity to Poco Bueno
within seven generations (Rashmir-Raven et al., 2013). Today, carrier frequency of the
HERDA-causing mutation is estimated at 3.5% in the overall American Quarter Horse
population but estimated at 28.3% in elite cutting horses (Tryon et al., 2009). HERDA is
now reported as one of the most common diseases in the equine industry, reported in
Quarter Horses, Appaloosas, and American Paint Horses. In a study of Brazilian Quarter
Horses, Borges’s group (2005) estimated HERDA allele and carrier frequencies at 2.9%
and 5.8%, respectively (Badial et al., 2015; Rendle et al., 2010; Tryon et al., 2009; White
& Bourdeau, 2011). HERDA is a world-wide issue without a cure that many horse
owners encounter.
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Genetically Testing Equine for HERDA
In order to prevent the spread of HERDA, the AQHA (2018) requires breeders to
complete the DNA (parentage) and panel tests on stallions and report which mares were
bred. They offer a five-panel genetic test which covers HERDA, glycogen branching
enzyme deficiency, hyperkalemic periodic paralysis, malignant hyperthermia, and
polysaccharide storage myopathy. Breeders may order a kit online through the AHQA
website and mail in a DNA sample of about 50 tail hairs for genotyping, where samples
are processed by the University of California-Davis for HERDA. Current panel tests cost
$100 for AQHA members or $155 for nonmembers, and results may be obtained in about
two weeks. Some universities offer HERDA genotyping services, diagnosing through
Restriction Fragment Length Polymorphism (RFLP) analysis (University of CaliforniaDavis) where the difference in homologous DNA sequences can be detected by the
presence of differing PCR fragments after restriction enzyme digest (Figure 5A), or
sanger sequencing (Figure 5B) (Texas A&M University) (Heather & Chain, 2016) NCBI,
2017).
Although several groups refer to horse zygosity for the HERDA-causing mutation
differently, this thesis project refers to the three genotypes as wild type (WT/WT);
carriers (WT/Hrd), which are heterozygous for the HERDA-causing mutation, and
(Hrd/Hrd) which are homozygous for the HERDA-causing mutation.
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Figure 5. Genotyping Horses for the HERDA-causing mutation. A) Restriction
Fragment Length Polymorphism (RFLP) analysis where DNA fragments are sorted by
length in gel electrophoresis and B) Sanger Sequencing to identify the HERDA-causing
mutation in equine. The horses Coralee, Eunice, and Eileen are wild type (WT/WT); Nike
and Solo carry the mutation (WT/Hrd) and Max is homozygous for the mutation
(Hrd/Hrd). The HERDA mutation is circled in red, the mutant glycine to arginine change
(p.39G>R) is boxed in yellow. The blue arrow indicates the double peak for HERDA
carriers.

Molecular Basis for HERDA
The HERDA-causing mutation, located on equine chromosome 1 (ECA1), was
identified by Tryon’s group (2007), with fine-structure single nucleotide polymorphisms
(SNPs) mapping. They compared the HERDA PPIB gene sequence to other species such
as human, chimpanzee, dog, cow, mouse, and Quarter Horses (Figure 6). They identified
the correlation between the HERDA-causing mutation (c.115G>A) and HERDA-affected
individuals in results from assaying samples of 64 HERDA-affected horses with a control
group of 1079 horses. Additionally, extracellular cyclophilins, such as cyclophilin B
(cypB) of the PPIB gene, have been reported to be associated with procollagen
processing and inflammatory response (Arora et al., 2005; Bachinger, Morris, & Davis,
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1993; Smith, Ferreira, Hebert, Norris, & Sauk, 1995; Steinmann, Bruckner, & SupertiFurga, 1991).

Figure 6. HERDA PPIB Protein Alignment. Equine PPIB shares 97% identity with
canine PPIB, while it is 88% identical with the six-mammalian species in this figure.
*HERDA-causing mutation (c. 115G>A), results in a glycine to arginine change (p.
39G>R) in the putative N-terminal domain of the cyclophilin B protein, otherwise
conserved in all other sequenced vertebrates. (Tryon et al., 2007).

CypB has been shown to play a major role in the biosynthesis of procollagens, as
it interacts with the many collagen-modifying enzymes, such as P3H1-CRTAP-CypB
complex, calnexin, calreticulin, calmegin, HSP47, and protein-disulfide isomerase
(Chang, Barnes, Cabral, Bodurtha, & Marini, 2009; Ishikawa, Vranka, Wirz, Nagata, &
Bächinger, 2008; Kozlov, Määttänen, Thomas, & Gehring, 2010; Smith et al., 1995; J.
Zhang & Herscovitz, 2003). CypB participates in proline residue 3-hydroxylation, and
after triple helix formation, CypB and other cyclophilins catalyze the rate-limiting step of
peptide bond cis-trans isomerization (Bächinger, 1987; Bachinger et al., 1993; Steinmann
et al., 1991). Procollagen then folds with the assistance of special chaperones including
HSP47 and FKBP65 as likely candidates (Ishikawa et al., 2012, 2008; Makareeva &
Leikin, 2007). Ishikawa’s group (2012) discovered that the HERDA-causing mut-CypB
protein has a disordered side chain where Arg-6 predominantly occupies the position of
normal lys-5 (Figure 7), displacing the main chain and preventing normal interaction with
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the P-domain of procollagen modifying enzymes and chaperones. They suggest that
mutCypB’s interactions with collagen-folding chaperones results in delayed collagen
folding in this rate-limiting step, affecting its secretion into the extracellular matrix,
which was confirmed when they detected decreased hydroxylysine residues in collagen
fibrils from HERDA-affected equine.

Figure 7. HERDA PPIB (CypB) Crystal Structure. Three superimposed crystal
structures of horse WT CypB (green), horse HERDA mut-CypB (red), and human WT
CypB (white) in a duplex with the proline-rich P-domain of calmegin (yellow). Note the
displacement of Lys-5 (green arrow) and occupation of normal Lys-5 position by Arg-6
(shown as sticks; indicated by orange arrow) in HERDA CypB, leading to significant
displacement of the main chain and preventing normal interaction with calmegin’s Pdomain. Although only calmegin P-domain is shown here in complex with CypB, the Pdomains of several procollagen modifying enzymes and chaperones interact with CypB,
such as calreticulin, lysyl hydroxylase 1 the P3H1-CRTAP-CypB complex, and others
(Ishikawa et al., 2012)
Ehlers-Danlos Syndrome
HERDA is clinically similar to Ehlers-Danlos syndrome type VIA (EDSVI) in
humans, which is categorized within a larger group of connective tissue fragility
syndromes (A. Rashmir-Raven, 2013). Ehlers-Danlos Syndrome (EDS) is caused by
mutations in genes encoding various collagen types, collagen-modifying enzymes, and
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other critical components of the dermal extracellular matrix (Mao & Bristow, 2001a;
Myllyharju & Kivirikko, 2004a; Seidler et al., 2006). EDSVI is caused by a deficiency of
lysyl hydroxylase 1 due to PLOD1 gene mutations and is inherited autosomal recessively
(Hautala, Heikkinen, Kivirikko, & Myllyla, 1993; Wilcox, 2003). EDSVI is characterized
by hypotonia (muscle weakness) at birth; progressive kyphoscoliosis (abnormal posterior
and sideways curvature of the spine); skin hyperelasticity and fragility; joint
hypermobility and subluxations; microcornea; rupture of arteries and the eye globe;
and/or osteopenia (bone weakness) (Beighton, De Paepe, Steinmann, Tsipouras, &
Wenstrup, 1998). Occurrence of EDSVI in humans is estimated at 1:100,000 (Yeowell &
Steinmann, 2014). Classical EDS of hypermobile and classical forms are most common,
affecting between 1 in 5,000 to 20,000; other forms of EDS are rare, often linked to
affected families (Tilstra & Byers, 2002).

A

B

Figure 8. Phenotypic Similarities between HERDA and Ehlers-Danlos Syndrome. A)
Hyperextensible skin in a human patient affected by Ehlers-Danlos syndrome (Malfait,
Wenstrup, & De Paepe, 2010) and B) hyperelastic skin characteristics in HERDAaffected equine (White, 2014).

Mutations affecting enzymes involved in post-translational modification of
collagens have been associated with autosomal recessive forms of EDS in humans and
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with similar recessive syndromes in animals (Colige et al., 2002; Mao & Bristow, 2001b;
Myllyharju & Kivirikko, 2004b). The most common mutations for Ehlers Danlos affected
humans occur in collagen genes, with 75% occurring in Col5A1 gene, while null
mutations in LEPRE1 and CRTAP cause severe recessive osteogenesis imperfecta
(Marini, Cabral, & Barnes, 2010; Ritelli et al., 2013; Symoens et al., 2012).
Two novel mutations in the PPIB gene were recently reported by Jiang’s group
(2017) in a rare pedigree from a Chinese cohort with autosomal recessive osteogenesis
imperfecta type IX. With next-generation sequencing (NGS), they sequenced the parents’
whole exomes, revealing that the father carried a PPIB (c.25A>G) mutation in exon 1 and
the mother carried a PPIB (c.509G>A) mutation in exon 4. These human cases of EDS
hypermobility type (HEDS) represent the most similarity to the HERDA-causing
mutation (c.115G>A) in location and type, where gene editing the HERDA-causing
mutation in equine could potentially serve as a model for curing EDS in humans.
EDS has been observed in Quarter Horses, not affected by HERDA. In one study
by Steelman’s group (2014), a 7-year-old black Quarter Horse gelding, in good body
condition, had a 12-month history of skin lesions and scarring but did not exhibit joint
hypermobility or ocular abnormalities normally associated with the HERDA, nor did it
have any relation to HERDA-affected horses. The group performed a necropsy, which
revealed fibrous lesions of the withers and tenting lesions on dorsal skin (Figure 9).
Additionally, they found that collagen fibers were slightly fragmented and tissue layers
were separated throughout the skin. Although they did not discover a genetic mutation as
a cause for this case report, the group hypothesized that a novel and likely spontaneous
mutation in the many collagen synthesizing, propeptide cleaving, or folding associated
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proteins is responsible for the observed Ehlers-Danlos symptoms, and suggests that
horses with similar clinical signs without the PPIB mutation should be classified as
having EDS.

Figure 9. Non-HERDA Clinical Signs of Ehlers-Danlos in Equine. Gross lesions
revealed by autopsy of a 7-year-old gelding with Ehlers Danlos syndrome, which tested
negative for HERDA. A) Skin tenting resulting from lesions. B) Dermal separation
characteristic of HERDA but observed in this equine with Ehlers Danlos (Steelman et al.,
2014).

CRISPR/Cas9
Since HERDA is caused by the single-nucleotide mutation (c.115G>A) in exon 1
of PPIB gene, several gene editing tools may be employed to genetically reverse it
(Paquet et al., 2016; Tryon et al., 2007). Type II CRISPR (clustered regularly interspaced
short palindromic repeats)/Cas9 (CRISPR associated protein 9) is derived from the
adaptive prokaryotic immune system and targets genomic DNA sites, guided by short
single-stranded guide RNA (sgRNA). After Cas9 binds to target loci, it nicks both strands
of DNA, generating double strand brakes (DSBs) which generally result in indels but
with a donor oligonucleotide template present, can stimulate cellular repair machinery to
incorporate desired edits to genomic DNA (Cong et al., 2013a). CRISPR/Cas9 has
improved the efficiency of genetic engineering which replaces previous gene editing
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tools like designer zinc fingers (ZFs), transcription activator-like effectors (TALENs)
which required homodimer formation (McCarty, Kleiger, Eisenberg, & Smale, 2003).

Figure 10. Targeting Genomic DNA with CRISPR/Cas9. Schematic representation of
CRISPR/Cas9 targeting genetic loci and inducing DSBs. After complexing with the guide
RNA, Cas9 is directed to a gene of interest, cuts both DNA strands, and triggers DSB
repair, which may result in indels or HDR which may introduce desired edits if an
oligonucleotide donor is present (Ding, Li, Chen, & Xie, 2016).
CRISPR loci in the bacterial genome are composed of DNA repeat sequences (2148bp) that are flanked with spacers (27-72bp), as observed in Thermophilus bacterial
response to phage infection during milk fermentation (Labrie, Samson, & Moineau,
2010). Many phage-resistant bacteria carry CRISPR-Cas systems with multiple repeat-
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spacers identical to the infectious phage genomic sequences; for example,
Methanococcus jannaschii contains up to 20 CRISPR loci in its genome, and CRISPR
loci can be transferred horizontally via conjugation (Deveau, Garneau, & Moineau,
2010). Defense against phages occurs in two phases: adaptation and interference (Agari
et al., 2010; Horvath & Barrangou, 2010). Adaptation refers to the process of bacteria
acquiring short fragments of invading phage DNA and integrating them into their
genomes (Brouns et al., 1993; Browne, Li, Chong, & Littman, 2005; Bult et al., 1996).
Interference refers to the Cas complex binding CRISPR RNA (crRNA) from the CRISPR
locus and cleaving foreign DNA which matches the previously integrated spacers which
threaten to integrate into the host’s DNA (Agari et al., 2010).
Engineering the Cas9 System
Cas9 is composed of six domains, REC I, REC II, Bridge Helix, PAM Interacting,
HNH and RuvC. REC I binds guide RNA; the role of REC II is not yet well understood;
the Bridge Helix domain is crucial for initiating cleavage activity upon binding of target
DNA; the PAM Interacting domain confers PAM specificity for discriminating between
self and nonself sequences, and is responsible for initiating binding to target DNA; and
HNH and RuvC are nuclease domains that cut single-stranded DNA (Anders,
Niewoehner, Duerst, & Jinek, 2014; Jinek et al., 2014; Nishimasu et al., 2014). The
sgRNA is composed of two parts; tracrRNA which binds Cas9, paired to the crRNA,
which base pairs with the target DNA, forming a heteroduplex(Cong et al., 2013; Jiang &
Doudna, 2017). These two RNAs are oftentimes delivered as a single-guide RNA
(sgRNA), where after complexing with Cas9, lead it to cut DNA at endogenous genomic
loci adjacent to the PAM, as shown in human, mouse, and other mammalian species,
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including the golden Syrian hamster as demonstrated by our laboratory (Cong et al.,
2013a; Fan et al., 2014).
A critical step in genome editing is designing an efficient guide RNA to target the
genomic site of interest while accounting for possible off-targets. Guide RNA scoring
software is available for SpCas9, and some Cas9 variants, through many online tools
which use metrics from large-scale, empirical data to optimize sgRNA design, to enable
precise and efficient genome engineering (Doench et al., 2016). Recently, new rules for
guide RNAs were discovered, where TT- and GCC-motifs located in the 4 PAMproximal bases of the targeting sequence block CRISR/Cas9-mediated gene editing
(Graf, Li, Chu, & Rajewsky, 2019). Additional factors such as decreased chromatin
accessibility, secondary structure formation, or potential off-target DNA sites may also
affect the choice and efficiency of sgRNA design (Cong et al., 2013a).

Figure 11. Indels from CRISPR/Cas9 Double Strand Breaks. Insertions or deletions
(indels) detected via sequencing, in EMX1 locus of human 293FT cells edited by human
codon-optimized SpCas9 plasmid (Cong et al., 2013). The red dashes represent deletions,
and red letter is an insertion. Note the PAM sequence overlined in red, Cas9 cleavage site
indicated by the purple arrow, and the protospacer in blue.

The PAM is crucial for Cas9 binding genomic DNA, a sequence specific to the
species of Cas9, but in most commonly used, SpCas9’s PAM is composed of three
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nucleotides in the order NGG after the 3’ end of the protospacer sequence which occurs
every 16bp on average within the human genome (Figure 11) (Cong et al., 2013; Hu et
al., 2018). The frequency of the PAMs within a gene of interest is vital to the success of
homology directed repair (HDR)-mediated gene editing, which require precise
positioning and short cut-to-mutation distances (~10-20bp away), respectively, for
efficient editing (Paquet et al., 2016). Due to the infrequency, or to overcome a great
distance of NGG PAMs from genetic locus to be edited, Cass proteins from more than
20 bacterial species, requiring PAMs such as NGRRT, NGRRN, NNNNGATT,
NNNNRYAC, NNAGAAW, or NAAAAC have mediated gene editing in a variety of
cell types, while thousands more Cas proteins remain to be discovered (Amrani et al.,
2018; Kim et al., 2017; Kleinstiver et al., 2015; Koonin & Makarova, 2013). These
orthologues’’ sequences are limited in their similarity, except for conserved HNH and
RuvC nuclease domains, and vary highly in length (~900-1600 amino acid residues)
(Jiang & Doudna, 2017). SpCas9 is the most commonly used Cas9 version with a length
of 1,369 amino acids, which limit its application for therapeutics, where shorter
orthologues such as Staphylococcus aureus Cas9 (SaCas9) which is 1kb shorter than
Cas9 or Cas-X which was isolated from a non-pathogenic bacterium with the intent of
reducing the human pre-existing adaptive immune response. These Cas traits are
desirable therapeutic applications such as packaging into viral vectors like AAV (~4.7kb
DNA storage) and preventing an immune response in those receiving treatment
(Charlesworth et al., 2019; Kleinstiver et al., 2015; Liu et al., 2019; Wang et al., 2016).
Although many new Cas9 variants are discovered frequently, none are more
efficient than SpCas9 in editing mammalian cells with a PAM less restrictive than NGG

24

(Hu et al., 2018). Engineered variants of SpCas9 such as Sniper-Cas9, xCas9-3.7, SpCas9-NG and others have been developed by directed evolution, resulting in higher
specificity to reduce off-targets, and/or greater PAM recognition flexibility, for
increasing the number of genomic sites where genome editing may occur (Hu et al.,
2018; Lee et al., 2018; Mazhar, Hill, & McAuliffe, 2018).
Another RNA-guided DNA-cutting nuclease known as Cas12a (Cpf-1) has been
recently adapted for genome editing, which processes its own guide RNA and recognizes
TTTV PAMs, generating staggered or “sticky” ends after DNA cleavage, 18-23nt distal
to the target site (Yamano et al., 2016; Zetsche et al., 2015). Recently, Gao’s group
(2017) has engineered Cas12a variants through structure-guided mutagenesis, which
increased its targeting range three-fold, to one cleavage site per ~11bp in human coding
sequences. These Cpf-1 TYCV and TATV PAM-recognizing variants show enhanced
performance in human cells and high DNA-targeting specificity, qualities which are
invaluable for editing NGG PAM-scarce loci (Gao et al., 2017).
CRISPR/Cas9 DNA Breaks – DNA Repair
One study in humans reported that DNA damage occurs naturally at an estimated
20,000-100,000 times a day, with DSBs being the most deleterious (Khanna et al., 2001).
Originally observed by gamma irradiation, DSB repair was theorized to use broken ends
with homologs and later proven to use sister chromatin as templates for repair (OrrWeaver, Szostak, & Rothstein, 1981; Resnick, 1976). If not repaired, DSBs can induce
apoptosis, loss of heterozygosity through copying sequences from sister chromatids, cell
senescence, or cancer (Burma, Chen, & Chen, 2006).
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The non-homologous end joining (NHEJ) pathway directs the religation of
segregated DNA, while not requiring a homologous template. Due to the presence of
repeats or microhomology, miscellaneous nucleotides at the DSB site are deleted to allow
for rejoining of the strands (Figure 12) (Jasin & Rothstein, 2013; Weterings & Chen,
2008). The steps of NHEJ include (I) DNA end recognition, (II) DNA end bridging, (III)
DNA end processing, and (IV) ligation of broken ends, which result in insertion or
deletion of DNA bases at the DSB site, making NHEJ pathway a generally unfavorable
pathway for genome editing (Davis & Chen, 2013).

Figure 12. Double Strand Break Repair Pathways. (Jasin & Rothstein, 2013).

The Homology Directed Repair (HDR) pathway uses an undamaged DNA strand
as a template for repairing the damaged strand, such as a sister chromatid or
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synthetically-produced DNA (J. P. Zhang et al., 2017). The first step of HDR is 5’ to 3’
end resection, which leaves a 3’ ended single-stranded DNA (ssDNA) region
(Kakarougkas & Jeggo, 2014). Replication protein A (RPA) quickly binds ssDNA tails to
prevent secondary structure formation, followed by RAD51 tail binding, which displaces
RPA, and promotes invasion onto the undamaged template and strand displacement,
forming a D-loop structure which provides a 3’ end for DNA synthesis or gap filling by
polymerase, resulting in a heteroduplex molecule called a double Holliday Junction (dHJ)
(Figure 13) (Jasin & Rothstein, 2013; Kakarougkas & Jeggo, 2014). Many HDR avenues
may follow, but to avoid cross-over events, endonucleases induce symmetrical incisions
across the junctions, resulting in nicked duplex products (Shah Punatar, Martin, Wyatt,
Chan, & West, 2017). The newly synthesized DNA strand disassociates from the D loop,
dissolved by branch migration and topoisomerase activity of the BLM
(Sgs1)/TOP3α/RMI1 complex, and anneals to the other DNA end, followed by endligation which finishes the DNA repair event (Jasin & Rothstein, 2013).
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Figure 13. Homology Directed Repair after Double-strand Break Formation. (Shah
Punatar et al., 2017).

The HDR pathway may be used to insert exogenous DNA sequences into the
genome, enabling generation of site-specific knock-ins (Gutschner, Haemmerle,
Genovese, Draetta, & Chin, 2016). HDR-mediated knock-in efficiencies may reach 10%
in mammalian cells when used in conjunction with donor molecules which are necessary
for providing a template for the cell’s repair machinery to read and insert altered gene
sequences (Jasin & Rothstein, 2013). These homology donors may range from short
single-strand oligodeoxynucleotides (ssODNs) with 50-100bp homology arms, to larger
external linear sequences with circular or linearized donor template with 1kb or longer
flanking arms to achieve knock-in of larger reporter genes, which has been achieved in
many cell types, including human cells via CRISPR/Cas9-induced HDR (Chen et al.,
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2011; Radecke, Radecke, Cathomen, & Schwarz, 2010). According to findings from
three groups, led by Wang (2016), Richardson (2016), and Prykhozhij (2018), ssODN
optimization involves several factors including length, sense, symmetry, PAM mutations
and chemical modifications. These groups found that an optimal ssODN design included
a length of 120nt., antisense orientation, asymmetric alignment to the DSB (77bp
upstream homology and 43bp downstream), a 1nt. PAM mutation and phosphorothioate
modifications to prevent endonuclease cleavage, increasing HDR 3 to 10-fold in Zebra
fish gene editing experiments.

Figure 14. Estimated CRISPR/Cas9 Editing Frequencies. As Cas9 cuts further away
from the mutation of interest, the lower the probability of isolating biallelically edited
zygotic clones. Heterozygous (blue) frequency climaxes at 10-15 bp away. Frequency of
homozygous wild type (green) increases with distance as frequency of homozygous
edited (red) decreases (Paquet et al., 2016).

In many instances, HDR is desired for knocking in a genetic sequence but it’s
difficult to achieve due to lower efficiency when compared to NHEJ. In the case of
single-nucleotide changes, HDR efficiencies depend largely on the distance-to-cut
mutation, preferably <15bp (Figure 14) (Paquet et al., 2016). Other ways to increase
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HDR events in cells include small molecule inhibitors of NHEJ, which are shown to
increase point mutation generation by up to 4-fold in some cell lines (Riesenberg &
Maricic, 2018). Alternatively, HDR booster chemicals SCR7, L755507, and Resveratrol
increased HDR by nearly 2-3 fold, and in some cases as high as 50% in screened
colonies (Li et al., 2017). Additionally, Integrated DNA Technologies (IDT) has
developed a proprietary Alt-R HDR chemical enhancer (Schubert, Thommandru, and
Wang, 2018). Although HDR enhancers and NHEJ inhibitors have increased HDR in
many cases, these chemicals do not have universal effects on all cell types and targeted
genes and may not increase efficiency or may alter cell growth (Riesenberg & Maricic,
2018).
Adenine Base Editors
Gaudelli (2017) from David Liu’s group at MIT developed an Adenine Base
Editor which converts A∙T to G∙C pairs in genomic DNA without DSBs. Her 7th
generation Adenine Base Editor (ABE7.10) contains a Cas9 nickase fused to Escherichia
coli TadA, a tRNA adenosine deaminase, which was adapted through extensive directed
evolution and protein engineering to act on DNA instead of its usual RNA substrate. She
reported that ABE7.10 requires an NGG PAM and a 20nt guide RNA to target genomic
loci to convert A to G within a base editing window which spans 5 nucleotides in
protospacer positions 13-17 from the PAM and is sometimes referred to as window
positions 4-8 on the PAM-containing strand (Figure 15A). She also described the
mechanism for base conversion where Cas9n binds and nicks genomic DNA, and TadA
hydrolytically deaminates adenosines to inosine within the editing window. In order to
complete the base conversion, Gaudelli reported that during subsequent DNA repair or
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replication, inosine is permanently replaced by guanosine and the complimentary
thymine base is changed to cytosine, and virtually no indels are generated (typically
≤0.1%).
If no NGG PAMs are available to adjust the target adenine within the editing
window, ABE 7.10 cannot be used to correct the mutation. To increase PAM flexibility,
Hu (2018) from David Liu’s group engineered the SpCas9 so that it recognizes NG,
GAA, and GAT PAMs, and fused it to TadA, resulting in xCas9(3.7)ABE7.10. He notes
in the study that editing efficiencies with these candidate PAMs vary by selection and
additionally by guide sequence design.
Additionally, to improve the already reliable ABE7.10, it was optimized by
modification of nuclear localization signals and codon usage, and ancestral reconstruction
of the deaminase component to increase plasmid expression Koblan (2018) from David
Liu’s group. The resulting ABEmax editor corrects mutations ~5 to 7-fold more
efficiency than ABE7.10 and generates indels rarely (≤1.6%) although elevated from the
virtually undetectable indel levels of ABE7.10 (Koblan et al., 2018).

Figure 15. Adenine Base Editor 7.10 Editing Window (A) Adenine DNA Base Editor
and (B) Adenine RNA Base Editor (REPAIR). DNA ABEs contain one WT TadA
deaminase and one evolved TadA deaminase to act on DNA. Base editing window is
shown for ABE 7.10 (Molla & Yang, 2019).
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It was also discovered that the editing window may be widened to accommodate
mutations which fall outside the editing window by Ryu’s group (2018). By adjusting the
guide length 1-2nt for a desired position (Figure 16), ABE editing windows are
broadened to protospacer positions 12-20. He showed that adenine base editing at the
distant 18 and 19 protospacer positions reached 20% in HEK293T cells, demonstrating
that the editing window may be adjusted to accommodate adenine base conversion at
distant positions which are unattainable with a 20nt. guide RNA.

Figure 16. Base Editing with Broadened Protospacers. AG editing in HEK293T
cells outside of conventional protospacer positions 12-17 by delivering lengthened
sgRNAs. About 10-12% normal efficiency at protospacer position 19 (blue arrow),
compared to that of the ideal target position 16. Since the HERDA mutation lies at
position 19, delivery of 22nt. sgRNA could allow for base editing as high as 10% (Ryu et
al., 2018).
Cas13 mRNA Editor (REPAIR)
In 2017, Gootenberg, Abudayyah, and Cox (2017) from Feng Zhang’s lab at MIT,
developed an RNA base editing system composed of type VI CRISPR-Cas which
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contains the programmable single-effector RNA-guided RNase, Cas13 which is capable
of robust knockdown and RNA editing by dCas13 to direct A to I conversion by
Adenosine Deaminase that acts on RNA (ADAR) in mammalian cells, referred to as
RNA Editing for Programmable A to I Replacement (REPAIR). They reported that
Cas13 does not require a PAM to target RNA, but is differentially regulated by accessory
proteins Csx27 and Csx28. They designed 51 nucleotide sgRNA to target mRNA
transcripts with REPAIR, containing a C mismatch at the target A in the guide. This
“base flip” directs the ADAR2 enzyme to deaminating the target A, exposed in a bulge or
loop (Matthews et al., 2016). They reported that efficiency of REPAIR is dependent on
the position of the target A in the guide sequence (as designated by the C base flip),
where the 34th position from the direct repeat provides the best editing, and a 5' G may
be appended to cap the guide which increases efficiency.
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CHAPTER III
MATERIALS AND METHODS
Cell Culture
Equine skin sample collections for genetic analysis and genome editing were
taken from a privately owned HERDA-affected horse named Max, and a Utah State
University owned horse named Badger (IACUC-2771). The biopsies were sanitized with
ethanol, washed in PBS, submerged in DMEM while resectioned into tiny pieces, and
placed in at 100mm cell culture dishes with 10% or 20% FBS DMEM for several days at
37o C, 5% CO2 to allow for outgrowth of fibroblasts from the tissue fragments (Table 1).
The cells were then trypsinized, expanded in T-75 flasks, and cryopreserved.
Gene Targeting in HERDA Equine Fibroblasts
To target the PPIB genomic loci in HERDA equine fibroblasts, RNA guides were
designed with Benchling life science data management/collaboration platform tool
(https://www.benchling.com). Primers for sgRNA synthesis and oligonucleotide repair
templates for the targeting sites were synthesized by Integrated DNA Technologies (IDT,
Iowa, USA). sgRNAs were synthesized “in house” via GeneArt™ Precision gRNA
Synthesis Kit (Thermo Fisher Scientific) according to the manufacturer’s protocol. 2 μg
sgRNAs were complexed with 2 μg Cas9 protein (Trucut©, Thermo Fisher Scientific) at
room temperature for 15-30 minutes, forming the ribonucleoprotein (RNP) (Table 1).
5x105 HERDA fibroblasts were transfected using AMAXA 4D nucleofection (Program
EN-150) according to the manufacturer’s protocol with sgRNA3 RNP and ssODN RC7
(PAGE purified single stranded DNA donor oligonucleotide (IDT) 100uM final
concentration) (Table 3). The CRISPR/Cas9 RNPs and ssODN RC7 were transfected into
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fibroblasts derived from a HERDA-affected horse named Max (Hrd/Hrd). Negative
controls were derived from untransfected Max cells and positive controls from nonaffected and untransfected horse (WT/WT) fibroblasts.
Cells were grown for 2 days, after which half of cells were harvested for
genotyping. Genomic DNA was extracted with the DNeasy blood and Tissue Kit
(Qiagen, Cat No./ID: 69506) according to the manufacturer’s protocol (Table 1).
The PPIB gene containing the HERDA mutation was amplified using PPIBex1F
forward primer and PPIBex1R reverse primer (Table 2). Each 50 μl PCR reaction was
assembled with 0.25 Ex Taq Polymerase (Clonetech) according to the manufacturer’s
instructions using 1 μM forward and reverse Pub1 primers. PCR reactions were carried
out under the following conditions: 98⁰C for 2 min, then 32 cycles of 98⁰C for 10 sec,
60⁰C for 30 sec, 72 for 30sec, then final extension 72⁰C for 5 minutes. PCR products
were verified by comparison to DNA standard (1-kb Plus DNA Ladder) and to WT or
HERDA controls on a 2% agarose gel with SYBR Safe DNA stain (Life Technologies)
(Table 1). 2-3 μl of PCR product were digested with Stu1 (Eco 1417) (Thermo Fisher
Scientific) at 37⁰C for 15 minutes to check for editing, or the with Taa1 (Thermo Fisher
Scientific) with the same parameters to check for indels. PCR fragments were loaded
onto a 2% agarose gel and compared to WT and HERDA control digests along with 1-kb
Plus DNA ladder (Table 1). Since Stu1 cuts PCR product containing HERDA, bands at
250bp were classified as WT, and those lower at 120bp were considered HERDA. Gel
image analysis was performed using Image J software (1.47p, NIH) to quantify band
relative intensity for knockout and editing efficiencies. SYNTHEGO ICE, a CRISPR
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poly peaks parser analysis tool, was used to found in mixed PCR sequences for
estimating INDEL species in single colonies or pooled PCR.
HERDA Single-Colony Selection:
One-third of transfected cells were detached 2 days after transfection and pipetted
into 2mL fresh media for counting and establishing single-cell derived colonies by
limiting dilution, and the other two-thirds were cryopreserved. The average cell count
was performed with a hemocytometer, where the appropriate volume was pipetted into
50mL fresh 20% FBS DMEM (Thermo Fisher Scientific) and distributed to 5 96-well
plates (Thermo Fisher Scientific) (Table 1). Cells were incubated for 10-15 days and
screened for single-cell colonies within cell-positive wells. Upon reaching at least 80%
confluency, cells were transferred to 24-well plates, and then to 6-well plates where onehalf of the cells were harvested for genotyping. If cells had monoallelic or biallelic
editing, 5x105 cells were cryopreserved per cyrovial by addition of 10% DMSO to 90%
DMEM (20%FBS), and placed in a -80oC freezer, then transferred to liquid nitrogen the
next day.
Gene Targeting with Base Editors xABE and ABEmax
xCas9(3.7)-ABE(7.10) plasmid (Addgene #108382), pCMV ABEmax plasmid
(Addgene #112095), guide vector PFYF 1320 EGFP Site#1 (Addgene plasmid #47511),
and pX330-SpCas9-NG (Addgene plasmid #117919) were purchased from Addgene
(https://www.addgene.org) (Table 1). These plasmids were received as bacterial stabs. To
amplify these plasmids, bacterial stabs were spread on agarose dishes (+amp) and
incubated at 37⁰ C for 12 hours. Colonies were selected and inoculated in 2ml amp+ LB
broth and cultured at 37⁰ C with shaking at 225rpm for 12 hours. xABE and pFYF1320
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plasmid-carrying colonies were isolated by Gene JET Plasmid Miniprep kit (Thermo
Scientific) according to manufacturer’s instructions, verified by enzyme digest and gel
electrophoresis (Table 1). Plasmids for sgRNA expression were constructed using onepiece blunt-end ligation of a PCR product with the KLD kit (New England Biolabs)
according to the manufacture’s protocol (Table 1). PCR was performed using Ex Taq
Polymerase (Clonetech) with guide sequence-containing primers and the guide
expression plasmid pFYF1320 as a template according to the manufacturer’s instructions.
DNA vector amplification was carried out using single-use JM109 competent cells
(Promega). Bacteria were transformed, cultured, and verified according to the
manufacturer’s instructions and as stated above.
Plasmid Transfection: 2 μg plasmid (xABE, ABEmax, or pX330-SpCas9-NG,
and 2.5 μg of sgRNA expression plasmid were mixed with 100 μl P3 solution (LONZA)
and transfected into 5x105 HERDA cells according to LONZA protocol; cells were
cultured and genotyped as stated according to methods stated above. The same procedure
was carried out with 2 μl GFP plasmid (LONZA) as a positive control, where although
not quantified, nearly every fibroblast was fluorescent under blue/UV light.

REPAIR Plasmid Preparations: pC0054-CMV-dPspCas13b-longlinkerADAR2DD(E488Q/T375G) (Addgene plasmid # 103870), pC0043-PspCas13b crRNA
backbone (Addgene plasmid # 103854), and pC0039-CMV-dPspCas13b-GSADAR2DD(E488Q) (Addgene plasmid # 103849) were purchased from Addgene
(https://www.addgene.org) (Table 1). pC0043 guide expression vector was linearized in
the following 100 μl reaction: 1500 ng BbsI-linearized vector DNA (pc0043), 10 μl
cutsmart buffer, 2 μl BbsI-HF, 85 μl H2O. The reaction was incubated at 37⁰C for 1 hour
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and inactivated at 65⁰C for 20 minutes. Digest with BbsI was purified using QIAquick®
PCR purification kit (Ref# 28106). For ligation, primers were ordered from IDT, melted
at 95⁰C for 2 minutes, then annealed by cooling to 25⁰C on bench top. Ligation reaction
included 2 μl T4 DNA ligase buffer, 50 ng vector DNA (pc0043 crRNA backbone), 2.5
ng annealed primers, 1 μl T4 DNA ligase (M0202), and 14 μl water (New England
Biolabs). Concentration of insert oligos was calculated using the NEB calculator.
Ligation proceeded for 10minutes on benchtop at room temperature and was inactivated
by incubation for 10 minutes at 65⁰C. 5 μl ligation product was transformed into JM109
competent cells (Promega) according to manufacturer’s instructions and incubated
overnight at 37⁰C with shaking (225rpm) on amp+ agarose. Colonies were selected and
inoculated in 2ml LB broth and cultured at 37⁰ with shaking at 225rpm for 12 hours.
Plasmids were isolated with the Gene JET Plasmid Miniprep kit (Thermo Scientific)
according to manufacturer’s instructions and verified by enzyme digest, gel
electrophoresis, and sequencing (ACGT Inc.; m13R primer 5′GGAAACAGCTATGACCATG- 3′). Colony 3.3 (positive for insert into pc0043) was
added to 50ml LB broth and incubated overnight at 37⁰C with shaking (225rpm). The
plasmid was purified from the bacteria using Plasmid Plus Midi kit (Qiagen, Ref#
12943).
REPAIR Transfection: 1.5 μg pC0054 or pC039 and 4 μg of sgRNA expression
plasmid (pC0043+insert) were mixed with 100 μl P3 solution (LONZA) and 5x105
HERDA equine cells and transfected according to LONZA protocol and repeated with
half the amount of plasmid. Cells were harvested after 48 hours in order to harvest
optimal amounts expected edited RNA transcripts. Medium was removed and cells were
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lysed by addition of 300 μl lysis buffer with 2-mercaptoethanol. Lysate was homogenized
by passing through an 18-gauge syringe needle. RNA was purified from lysate using the
PureLink® RNA Mini Kit (Life technologies, Cat# 12183018A) according to
manufacturer’s instructions. RNA was treated with DNase I after purification to assure
highly pure RNA without genomic DNA contamination (5 μl RNA, 2 μl DNaseI+buffer,3
μl water, room temperature incubation for 15min, 65⁰C for 10 min). cDNA was
synthesized using the SuperScriptTM III First-Strand Synthesis Super Mix according to
the manufacturer’s instructions (Invitrogen, Thermo Fisher Scientific). Each 20 μl PCR
reaction was assembled with 0.2 μl Ex Taq Polymerase (Clonetech) according to the
manufacturer’s instructions (2 μl buffer, 1.6 μl dNTP) using primers PPIBF2-RT,
PPIBR5-RT (Table 2) and 2 μl cDNA from previous reaction (unquantified). PCR
reactions were carried out under the same conditions as described above and genotyped
in the same manner.

Reagent
Cas9 protein (Truecut©)
GeneArt™ Precision gRNA
Synthesis Kit
KLD kit (two tubes: enzyme and
buffer)
SuperScriptTM III First-Strand
Synthesis Super Mix
pFYF1320 EGFP Site#1
pAsCpf1(TYCV)(BB) (pY211)
pC0043-PspCas13b crRNA
backbone
pC0039-CMV-dPspCas13b-GSADAR2DD(E488Q)

Company

Catalogue #

Thermo Fisher Scientific

A36498

Thermo Fisher Scientific

A29377

New England Biolabs

M0554S

Invitrogen, Thermo
Fisher Scientific
Addgene
Addgene

18080400

Addgene

103854

Addgene

103849

47511
89352
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pC0054-CMV-dPspCas13blonglinkerADAR2DD(E488Q/T375G)
xCas9(3.7)-ABE(7.10)
pCMV_ABEmax
pX330-SpCas9-NG
Stu1 (Eco 1471)
Taa1
BbsI
PureLink™ RNA Mini Kit
Agarose A
DNA ladder
Nunc™ Biobanking and Cell
Culture Cryogenic Tubes

Addgene
Addgene
Addgene
Addgene
Thermo Fisher Scientific
Thermo Fisher Scientific
New England Biolabs
Thermo Fisher Scientific
Bio Basic
Clonetech

103870
108382
112095
117919
FD0424
FD1364
R3539
12183018A
AB0013
3412B

Thermo Fisher Scientific
Thermo Fisher Scientific
Thermo Fisher Scientific
Thermo Fisher Scientific
Falcon, Life Sciences
Thermo Fisher Scientific
Sigma-Aldrich
Thermo Fisher Scientific
Promega
New England Biolabs

347783
25300054
11995115
14190250

Trypsin-EDTA (0.05%), phenol red
DMEM
DPBS
100mm Cell culture dish
FBS
16000044
DMSO
M81802
Gene JET Plasmid Miniprep kit
K0502
JM109 competent cells
200235
T4 DNA ligase
M0202
96-well Clear Flat Bottom TCtreated Culture Microplate
Falcon, Life Sciences
353072
LB Agar, Miller (Powder)
Fisher Scientific
BP1425500
Amplicillin
Sigma-Aldrich
A5354
Table 1. List of Reagents. Reagents used in experiments with respective companies and
catalogue numbers.
Name
PPIBex1F (Pub1F)
PPIBex1R (Pub1R)
PPIBF2-RT
PPIBR5-RT
Table 2. PCR primers

Sequence
5’-CGGTGGATGCTGCGTTTCT-3’
5’-TCCTAGGCTGGCTTGGGC-3’
5’-CTGTCTTCTTCCTGCTGTTGCC-3’
5’-TCTCCTTCAGACTACGGGGT-3’
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ssODN
Name

Sequence

length
(nt.)

symmetry

sense

RC7

5’−CAGGCAGGTCTGGAGAGGGGAGGCC
AGATCTTGACAGTGACTTTAGGCCCCTT
CTTCTTCTCATCGGCCGTGGAGGGTCCTG
GCAACAGCAGGAAGAAGA−3’

100

asymmetric

Antisense

*120nt

5’−AGGACCCTCCACGGCCGATGAGAAG
AAGAAGGGGCCTAAAGTCACTGTCAAA
GTCTGGCCTCCCCTCTCCAGACCTGCCTG
GCGAGGCCCGCCCTGGGGTCCGGCCTCG
GTGCCGCTGGT−3’

120

asymmetric

sense

Table 3. ssODN Designs. Sequences of ssODNs used in fibroblast transfections for
editing the HERDA-causing mutation in fibroblasts. *this ssODN was not shown to mediate
editing in pooled RFLP analysis, but may yet be useful for increasing HDR efficiency since it was a
late-stage ssODN design (Wang et al., 2016) for sgRNA3 that never had single-cell colonies
derived from a transfection.
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RESULTS
CRISPR/Cas9-medaited Gene Editing in Fibroblasts
sgRNA Designs, PCR-RFLP, Donor Oligonucleotides
The first approach used to edit the HERDA (c.115G>A) mutation in fibroblasts
was with CRISPR/Cas9 and ssODN templates. Since HDR efficiency in gene editing
decreases dramatically when DSBs are generated >15bp from the mutation, we designed
sgRNA1 (Table 4), which recognizes an AGG PAM resultant from the HERDA-causing
mutation, to generate indels 3bp upstream from the mutation. Reported as a unit less
on/off target score where values closer to 100/100 represent the best guide, sgRNA 3 had
the best predicted on/off target score, designed to generate indels 15bp downstream of the
HERDA mutation (Benchling guide scorer) (Table 4, Figure 17).

Equine PPIB Gene
~6kb

Figure 17. Targeting the HERDA-causing Mutation with CRISPR/Cas9. A segment
of genomic DNA from the horse PPIB gene that contains the HERDA-causing mutation
(red). Annotations include sgRNA sequences (highlighted in corresponding colors), their
corresponding PAM locations (underlined in brown).
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Guide name

Sequence (5’ to 3’)

sgRNA1

Predicted
on/off
target
scores
59/26

Observed
indel
efficiency

CGGCCGATGAGAAGAAGAAG

Mutationto-cut
distance
(bp)
3

sgRNA3

GAGGCCTAAAGTCACTGTCA

15

69/51

90%

sgRNA4

AGGCCTCTTCTTCTTCTCAT

11

53/34

none

sgRNA7

GCTGTTGCCAGGACCCTCCA

23

62/32

15%

PX330-NG-4

GAGAAGAAGAAGAGGCCTAA

4

n/a

55%

sgRNA3x22

AAGAGGCCTAAAGTCACTGTCA 15

n/a

n/a

none

Table 4. Guide RNA Designs. Details of sgRNAs tested in equine fibroblasts with the
HERDA-causing mutation.

Testing sgRNA Efficiency
A major challenge to designing sgRNAs for editing the HERDA-causing mutation
was that three GAA repeats are found upstream of the mutation, resembling a figurative
NGG PAM “desert”. We also suppose that these GAA repeats formed secondary
structures when incorporated into sgRNAs, preventing sgRNA1 and sgRNA4, which
spanned these GAA repeats, from generating indels (analyzed via RFLP). SgRNA 3 was
selected for gene editing because it generated indels 15bp downstream of the mutation,
with high efficiency (Figure 18C), while sgRNA 7 was the only other guide to generate
indels but at much further distance of 23 nucleotides from the HERDA-causing mutation.
Donor Oligo Design
Several oligonucleotides were designed for editing the HERDA-causing mutation
according to the findings of the Richardson (2016), Kankan (2016), and Paquet (2016)
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groups, for gene editing (Table 3). These oligonucleotides differed by length, symmetry
around the DSB, and sense with respect to the PAM-containing strand. An antisense
asymmetric ssODN donor template with 69 and 31 nucleotide homology arms was
designed, named RC7 (Reverse compliment 7). This ssODN carried two mutations:
R39G to edit HERDA and the sgRNA3 PAM-blocking mutation (AGGAGA) (Figure
18A).
Gene Editing Efficiency
CRISPR/Cas9 and ssODN (sgRNA3 and RC7) were transfected in fibroblasts
established from a HERDA-affected horse, named Max, which is homozygous for the
HERDA-causing mutation. RFLP analysis revealed that sgRNA 3 indel formation was
90% efficient (Figure 18C) while fragments resistant to Stu1 reached 20% (Figure 18D),
indicating that editing occurred.
HERDA
mutation
(c.115 G>A)

A
gDNA

sgRNA 3 site PAM
5’- CTCATCGTGGGCTCTGTCTTCTTCCTGCTGTTGCCAGGACCCTCCACGGCCGATGAGAAGAAGAAGAGGCCTAAAGTCACTGTCAAGGTCTGGCCTCCCCTCTCCAGACCTGCCTGGCGAGGCCCGCC -3’

RC7 AntisenseA
asymmetric
oligonucleotide

L

WT

Max

B

INDEL positive

3’- AGAAGAAGGACGACAACGGTCCTGGGAGGTGCCGGCTACTCTTCTTCTTCCCCGGATTTCAGTGACAGTTCTAGACCGGAGGGGAGAGGTCTGGACGGAC -5’

R39G

sgRNA 3
& ssODN

L
C

WT

Max

PAM mutation

sgRNA 3
& ssODN

L
D

WT

Max

sgRNA 3
& ssODN

44

Figure 18. CRISPR/Cas9 pooled DNA RFLP Analysis for Indels and Editing. A)
Genomic sequence and donor oligonucleotide RC7 (antisense, asymmetric) shown for
site PPIB G39R editing. B) sgRNA3 and ssODN RC7-transfected HERDA pooled PCR
product with WT and HERDA (Max) controls C) Taa1 enzyme digest which is
unaffected by HERDA point mutation editing or the PAM-blocking mutation, revealing
indels only, as uncut upper band and D) modified (diluted to 30 μl) Stu1 digest, revealing
editing and large indels as uncut upper band (blue arrow).
Screening Single-cell Derived Colonies
In order to determine point mutation editing efficiency in fibroblasts, 41 singlecell colonies were isolated and analyzed with RFLP and confirmed by sequencing.
Colonies 3D6, 1B6, and 3D5 had monoallelic editing and one colony, 3B2, had biallelic
editing. These colonies were cryopreserved for future experiments (Table 5). Overall
editing efficiency observed in single colony selection was 9.8% (4/41), while monoallelic
and biallelic frequencies were 7.3% and 2.4% respectively.
A

B
3D6

L

L

WT Max

3B2

3
B
1
C

L

WT

Max

1B6

D

L

WT Max

3D5
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Figure 19. CRISPR/Cas9 Single-Cell Colony RFLP Analysis and Sequencing. A)
colony 3D6 is monoallelically edited, B) 3B2 is biallelically edited, C) 1B6 is
monoallelically edited, and D) 3D5 (although small peaks) likely monoallelically edited.
RFLP fibroblast Controls: WT = WT/WT alleles, Hondo = WT/Hrd alleles, Max =
Hrd/Hrd alleles. Unlabeled lanes indicate unedited or indel-containing colonies. Blue
arrows and indicate point mutation editing (circled in red); green arrows indicate the
PAM-blocking mutation editing (circled in purple).

Colony
Name

Genotype

Vials
Cryopreserved

Cells per
cryovial

Confluency at
cryopreservation

Notes

3D6

WT/4-6bp
Deletion

5

5x105

90%

Very fast growth and good
morphology

3B2

WT/WT

2

5x105

90%

5

3D5

WT/HRD

2

5x10

90%

1B6

WT/1bp
Deletion

1

5x105

60%

Table 5. Gene Edited HERDA-equine Single-Cell Colonies. Colonies’ names and
genotype derived from sgRNA 3 and RC7 ssODN transfection and single-colony
selection.

ABEmax
Since sgRNA3 was highly efficient (90%), it was also used to base edit the
HERDA-causing mutation as the guide for ABEmax. sgRNA3 was lengthened by two
nucleotides for broadening the editing window to positions 12-19. This guide RNA
modification gave ABEmax access to the HERDA-causing mutation at position 19
(Figure 20).

22 21 20 19 18 17 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1
a

a

a

a

a

a

a

a

a

a

Figure 20. ABEmax Editing Diagram. The equine PPIB genomic sequence to be edited
with ABEmax contains the sgRNA3x22 sequence (annotated in green) and its
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corresponding PAM location (underlined in brown). The curly bracket indicates the
expanded base editing window location (positions 12-19) with the lengthened 22
nucleotide sgRNA. Complimentary strands are separated to demonstrate base editing
window.

After transfecting fibroblasts carrying homozygous HERDA mutation, gene
editing was not detected in pooled cells with the PCR-RFLP assay (Figure 21A) but after
deriving 20 single-cell colonies, monoallelic base editing was observed in three colonies
and confirmed by Sanger sequencing (Figures 21C and D). Seven other colonies were
also resistant to Stu1 digestion but unfortunately showed an unspecific PCR band just
below 250bp also apparent after Stu1 digestion (Figures 20B and C). When sequenced,
mixed peaks made the chromatogram difficult to interpret, indicating that the PCR
products contain an unrelated sequence and are unspecific bands, which can be further
investigated through TA cloning.

L

A

CL

1

WT

2

Max

3

4

ABEmax

5

6

B

7

L

8

1

9

2

10

3

4

5

L

6

11

7

8

12

9 10

13

11

14

12 13 14 15

15

16

16 17 18

17

18

19 20

19 20
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D
Colony 1

Colony 17

Colony 19

Figure 21. ABEmax Single-cell Colony RFLP and Sequencing Analysis. A) Pooled
RFLP for transfection with ABEmax and sgRNA3x22 showing no HERDA-edited cells.
B) PCR product from single and mixed colonies isolated from a 96-well plate. C) Digest
with Stu1 for editing detection. Colonies 1, 17, 19 show monoallelic editing. Colonies 36, 12-14 show editing and another possible indels (extra band).D) Sequence results from
single-cell colonies 1, 17, and 19 show double-peaks at the HERDA mutation, revealing
monoallelic adenine base editing, without indels. HERDA is circled in red and the blue
arrow indicates the double-peaks characteristic of heterozygotes.
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DISCUSSION
HERDA is an increasingly problematic genetic disease that remains difficult to
resolve in elite Quarter Horses throughout the world. “Breeding out” the disease by
carefully genotyping registered Quarter Horses for the HERDA-causing mutation may
reduce the spread of the genetic disease, but given the HERDA-causing mutation
frequency among elite American Quarter Horses, it is unlikely. Also, since there are no
effective treatments for HERDA-affected horses, they are oftentimes euthanized. Geneediting technology provides an opportunity to correct the HERDA-causing mutation.
In my thesis research, two gene editing strategies were successful in correcting
the HERDA-causing mutation in horse fibroblasts cultured from a HERDA-affected
horse. First, CRISPR/Cas9 nuclease with an ssODN template corrected either one or both
alleles in ~10% of transfected cells. Sanger sequencing confirmed that three single-cell
colonies derived from the transfection were edited monoallelically, and one biallelically.
These four colonies were cryopreserved with the goal of cloning the first gene edited
horses in this breeding line without HERDA. The second strategy used was adenine base
editing where ABEmax monoallelically corrected HERDA in 3 single-cell colonies
derived from a transfection. Seven other colonies showed likely editing, in which case
total ABEmax editing efficiency would be 55%, but an unspecific PCR band prevented
their genotyping by sequencing. Further investigation is needed to characterize the
genetic alterations in these colonies.
Transfection via nucleofection maximized the efficiency of the guide RNA used
for CRISPR/Cas9, generating 90% indels. Detecting editing in pooled cells with the
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PCR-RFLP assay was challenging, and determining editing efficiency from single-cell
colonies proved more reliable, but also time and work intensive. It is possible that gene
edited loci are selected against during PCR and/or digested in concentrated Fast Enzyme
Digest reactions. When enzyme digests were diluted to 30ul reactions, digests from
pooled DNA showed editing. Nevertheless, increased editing efficiency is paramount to
correcting HERDA in affected equine.
Novel CRISPR tools emerge at an accelerated rate, but their applicability to many
species, including equine, is unknown. We employed emerging gene editing techniques
to genetically edit equine fibroblasts homozygous for the HERDA-causing mutation and
demonstrated that both CRISPR/Cas9 combined with an ssODN and ABEmax are
efficient in editing the equine genome.
Although development may be costly to develop for actual treatment, we foresee
their use in gene editing fibroblasts established from champion Quarter Horses which
carry the HERDA-causing mutation followed by cloning animals from using the
mutation-corrected fibroblasts as nuclear donors. Cloning these performance horses could
offer horse breeders more flexibility in selecting mating pairs as edited clones could
propagate these elite genetic lines without instances of HERDA.
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CONCLUSIONS

The PPIB HERDA (c.115 G>A) mutation was efficiently targeted by
CRISPR/Cas9, generating 90% indels with sgRNA3 with a 15bp mutation-to-cut
distance. Cas9 nuclease-mediated editing reached 10% in HERDA-affected equine
fibroblasts. ABEmax was also used to target the HERDA mutation with sgRNA3,
lengthened 2nt. (sgRNA3x22). This allowed for using the highly efficient sgRNA3 with
ABEmax to edit HERDA at protospacer position 19, observed at 15% editing in singlecell colonies, but may be as high as 55% upon further analysis of unspecific PCR bands.
Other new technologies that emerged during this project were tested in HERDAaffected equine fibroblasts, including other Adenine Base Editors—xABE and REPAIR,
Nureki’s SpCas9-NG, and the Cpf-1 TYCV variant. Editing was not achieved with these
tools, except SpCas9-NG, which generated 50% indels only 4bp from the HERDAcausing mutation. Single-cell colonies from SpCas9-NG and ssODN transfections are
needed to determine editing efficiency, which were not analyzed due to time constraints.
Out of the 41 single-cell colonies derived from the CRISPR/Cas9 ssODN
transfection, four were edited—three monoallelically and one biallelically. These four
colonies were cryopreserved for later use in somatic cell nuclear transfer. Editing the
HERDA-causing mutation in horses may demonstrate whether the mutation is
responsible for high performance or if other genetic components independent of the
mutation contribute to their high performance. This precise gene editing could also
provide an alternative to “breeding out” the HERDA-causing mutation by retaining elite
performance horse genetics in edited clones, used for breeding.
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Additionally, HERDA gene therapies based on CRISPR/Cas9 and Adenine Base
Editor technology, which corrected the mutation in horse fibroblasts, could improve
affected equine health and performance. Restoring normal collagen folding, even at low
rates, could help affected horses perform in the American Quarter Horse industry, thus
reducing animal suffering and investment loss by owners.
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